"Healey & AMG Center for ALS announces new drug regimen for testing DNL343 in HEALEY ALS Platform Trial," published by the Sean M. Healey & AMG Center for ALS
The HEALEY ALS Platform Trial is adding a new investigational drug, DNL343, to continue to research new treatments for ALS (Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease).